St. Anton, Austria January 28-February 1, 2024
Registration
Opening Remarks
Session Chair
Organic Reactions in Aqueous Medium enabled by Surfactants (PL01)
Reagents and Catalysts with Translational Potential (PL02)
Coffee Break
From Batch to Flow: Advancing Synthetic Organic Chemistry through Technological Innovation (PL03)
Chemo-Biocatalytic Processes Enabled by a Continuous Flow Set Up (PL04)
Break
New Catalytic Approaches for Simplifying Complex Molecule Synthesis (KL01)
Welcome Reception, Sponsored by abcr
End of the day
Session Chair
Boron Based Heterocycles and their Application in Drug Discovery (PL05)
“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery (PL06)
Coffee Break
Deuterium in Drug Design: From Deuterium Switch to De Novo Drug Discovery (PL07)
New Functional Groups for Synthetic and Discovery Chemistry (PL08)
Outdoor Networking Activities
Networking Break
In Silico Prediction of Phase I and II Metabolism: Guiding Optimisation of Drug Metabolism o_BRCompany Workshop by Optibriumc_BR
Session Chair
Bicyclic Peptides as a Novel Therapeutic Modality (PL09)
Next-Generation Bioconjugates for Intra- and Extracellular Targeting (PL10)
Coffee Break
Creating Next-Generation Biotherapeutics Using Novel Chemistry Platform Technologies (PL11)
Exploring the Versatility of Covalent and Supramolecular Bioconjugation in ADC and AOC (PL12)
Poster Session 1 (odd numbers)
End of the Poster Session
Session Chair
Early Human Dose Predictions in Lead Optimization (PL13)
Early Human Dose Prediction & Machine Learning Models - Can We Impact Lead Selection? (PL14)
Coffee Break
SwiftPK: Development and Implementation of a High Throughput PBPK/PD Framework to Inform Drug Selection in Early Drug Discovery (PL15)
Predicting Human Exposure and Dose of Compounds Targeting the Brain (PL16)
Outdoor Networking Activities
Networking Break
Session Chair
Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Option for Acyclovir-Resistant Herpes Simplex Virus Infections (PL17)
Targeting Viral RNA Degradation Via Small Molecules As a Novel Antiviral Strategy to Achieve HBV Cure (PL18)
Coffee Break
Direct-Acting Antivirals with a Targeted Protein Degradation Mechanism (PL19)
Discovery of Obeldesivir; Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (PL20)
The Discovery of PAXLOVID (KL02)
End of the Scientific Programme
Conference Dinner
Session Chair
Light-Mediated Nickel Catalysis Enabled by Donor-Acceptor Ligands (PL21)
Coffee Break
Alkenes as Flexible Platforms for Asymmetric Transformations (PL23)
Attempts to Deliver on the Promise of Natural Product Synthesis (PL24)
Outdoor Networking Activities
Networking Break
AI for Medicinal Chemists: Novel Compounds Design and Retrosynthesis Prediction o_BRCompany Workshop by Iktosc_BR
Session Chair
NLRP3 Inhibitors for Neurodegenerative Disorders (OC01)
Discovery of a Bivalent Protein Kinase CK2 Inhibitor with Activity in Renal Cell Carcinoma (OC02)
Coffee Break
Discovery of BI 7446: A Potent Cyclic Dinucleotide Sting Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer (OC03)
Discovery of [18F]RoSMA-18-D6 for PET Imaging of Cannabinoid Type 2 Receptors (OC04)
Selective Inhibition of Tead Transcription and Impact on the Up-Stream Effector Kinases of the Hippo Pathway to Halt Metastatic Colorectal Cancer Cell Growth (OC05)
Poster Session 2 (even numbers)
End of the Poster Session
Session Chair
Deep Learning-Driven De Novo Drug Design Based on Gastric Proton Pump Structure (PL25)
Cryo-EM Enables Structure-Based Drug Design for Membrane Protein Targets at BI (PL26)
Coffee Break
Single Particle CryoEM at 200 kV & Itchy GPRCs (PL27)
Examples from Structure-Based Drug Discovery Using Cryo-EM at MSD (PL28)
Outdoor Networking Activities
Networking Break
Session Chair
Discovery of a Novel Oral NO- and Heme-Independent sGC Activator Runcaciguat (BAY 1101042) (OC06)
Heterocyclic Compounds as Delta-5 Desaturase Inhibitors (OC07)
Coffee Break
Novel Approaches to Molecular Glue Discovery: Design of Clinical Candidate NVP-DKY709 an IKZF2 Degrader by Re-Programming of CRBN Selectivity and Screening for Cooperativity Using DNA Encoded Libraries (OC8)
Discovery of LY3154885, a Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile (OC09)
Site-Selective C—H Oxidations for Late-Stage Functionalizations (KL03)
Closing Remarks